Stock AnalizAlkermes plc. ALKS
Biotechnology: Pharmaceutical Preparations · IPO 1991 · data as of November 13, 2026
Alkermes plc. (ALKS) is a healthcare company listed in the US with a market value of about $7.9B. In the twelve months to September 30, 2026 it had revenue of $1.8B and net income of -$351000, a net margin of -0.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 34.8, 5-year revenue growth of 7% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 66% below the current price.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B | $1.0B | $1.2B | $1.1B | $903M | $746M |
| Net income | -$351000 | $242M | $367M | $356M | -$158M | -$48M | -$111M | -$197M | -$139M | -$158M | -$208M |
| Free cash flow | $227M | $480M | $406M | $353M | -$17M | $74M | $41M | -$19M | $30M | -$32M | -$107M |
| EPS (diluted) | $-0.02 | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.29 | $-0.70 | $-1.25 | $-0.90 | $-1.03 | $-1.38 |
| Net margin | -0.0% | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% |
| ROIC | — | 11.2% | 22.9% | 20.8% | -0.3% | 5.6% | -6.0% | -12.7% | -5.3% | -7.9% | -13.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $57.74, 23% above the current price; targets range from $38.00 to $83.00; the consensus rating is “Buy”; expected EPS is $1.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Alkermes plc. stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 66% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alkermes plc. pay a dividend?
Not currently.
Is Alkermes plc. a good stock to buy?
We do not give buy or sell advice. Alkermes plc. scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.